Interleukin-1b (IL-1b) is a cytokine that shares with tumor necrosis factor (TNF) the ability to initiate largely similar signaling pathways, leading to proinflammatory gene expression. In contrast to TNF, however, IL-1b is not believed to induce tumor cell death. Here we demonstrate that prolonged treatment with IL-1b, in combination with interferon-c (IFNc), is cytotoxic for L929 tumor cells. IL-1b/IFNc-induced cytotoxicity requires only minimal amounts of IL-1b and shows morphological features of necrosis. Although TNF induces a similar response, we could exclude a contribution of endogenous TNF production in the effect of IL-1b/IFNc. Cell death in response to IL-1b/IFNc is independent of caspases, but requires the IL-1b/IFNc-induced production of inducible nitric oxide synthase (iNOS) and NO. Moreover, necrosis and iNOS/NO production could be prevented by treatment of the cells with a p38 mitogen activated protein kinase (p38MAPK) or IjB kinase b inhibitor. Altogether, these findings demonstrate that prolonged exposure to IL-1b plus IFNc induces L929 tumor cell necrosis, via a p38MAPK and nuclear factorjB (NF-jB)-dependent signaling pathway, leading to the expression of iNOS and the production of toxic NO levels.
Introduction
Interleukin-1b (IL-1b) and tumor necrosis factor (TNF) elicit a variety of biological responses, including the modulation of immunological, inflammatory and host defense mechanisms. The signal transduction pathways activated by TNF and IL-1b have been the focus of much interest because of the important role of these cytokines in multiple inflammatory diseases (O'Neill, 2006) . TNF also received much attention because of its ability to directly kill certain tumor cells, implicating the use of TNF in the treatment of cancer . Although TNF and IL-1b bind to different receptors, they activate largely similar signaling pathways leading to the activation of multiple transcription factors of which the activation of nuclear factor-kB (NF-kB) has been studied in most detail (Janssens and Beyaert, 2003; Viatour et al., 2005) . Both cytokines induce the recruitment to their receptor of a number of adaptor proteins, which function as a platform for the binding and recruitment of several other signaling proteins that have been described to participate in the post-receptor activation of IkB kinase b (IKKb) and stress-activated protein kinases such as p38 mitogen activated protein kinase (p38MAPK). In addition, TNF also induces cell death by either apoptosis or necrosis (Beyaert et al., 2002) . TNF-induced signaling leading to apoptosis is known in detail and involves the activation of different caspases. Moreover, TNF-induced proapoptotic signaling is negatively regulated by NF-kB (Kim et al., 2006a) , implicating the use of NF-kB inhibitors as a way to sensitize tumor cells to the cytotoxic effect of TNF. In contrast to pro-apoptotic signaling, TNF-induced signaling leading to necrosis is still poorly defined. Necrotic cell death is not the result of one well-described signaling cascade but is the consequence of extensive crosstalk between several biochemical and molecular events at different cellular levels (reviewed in Golstein and Kroemer, 2007) . Mitochondria-and NADPH oxidase-derived reactive oxygen species (ROS) are main players during the propagation and execution phases of necrotic cell death (Schulze-Osthoff et al., 1993; Kim et al., 2007) , directly or indirectly provoking damage to proteins, lipids and DNA, which culminates in disruption of organelle and cell integrity. The serine/threonine kinase RIP1 functions as a central initiator of TNF-induced necrosis, and has recently been shown to induce ROS production via the activation of Nox1 NADPH oxidase (Kim et al., 2007) . Whereas caspases play a crucial role in pro-apoptotic signaling, necrosis proceeds independently from caspases and has been proposed to involve calpain-induced lysosomal disruption and release of cathepsins (Golstein and Kroemer, 2007) . Necrosis occurs in both physiological and pathophysiological processes, and is capable of killing tumor cells that have developed strategies to evade apoptosis (Ricci and Zong, 2006) . Necrosis inducing stimuli may therefore be exploited in therapeutic strategies.
In contrast to TNF, IL-1b is believed not to exert any direct cytotoxic effects on tumor cells, although an antiproliferative effect of IL-1b on a number of tumor cell lines has been reported (Onozaki et al., 1985; Morinaga et al., 1989; Itoh et al., 1999) . IL-1b is also known to be cytotoxic for pancreatic b-cells, implicating a putative role for IL-1 in the development of type 1 diabetes (Cnop et al., 2005) . The biochemical mechanisms by which cells are killed by IL-1 are still poorly defined. IL-1b cytotoxicity on isolated human or murine islet b-cells requires the simultaneous presence of interferon-g (IFNg) and IL-1b for 4 days or more and is believed to depend on the expression of inducible nitric oxide synthase (iNOS) and NO production (Heitmeier et al., 1997; Rabinovitch and Suarez-Pinzon, 1998) . However, more recently the role of NO in IL-1b-induced b-cell death as well as the type of b-cell death has been debated (Liu et al., 2000) . Moreover, whether IL-1 induces similar signaling mechanisms in tumor cells has not yet been studied. Here we show that prolonged exposure of the L929 fibrosarcoma tumor cell line to IL-1b and IFNg induces cell necrosis by a mechanism that requires the activation of p38MAPK and IKKb, leading to the expression of iNOS and the production of toxic NO levels.
Results
Prolonged treatment with IL-1b in combination with IFNg is cytotoxic for L929 cells To study the cytotoxic effect of IL-1 and IFNg on cells different from b-cells, we decided to investigate the effect of IL-1 on L929 fibrosarcoma cells. These cells have previously been used in numerous studies on TNFinduced cell death (Vanhaesebroeck et al., 1991 (Vanhaesebroeck et al., , 1992 Beyaert et al., 1993) , but their sensitivity to IL-1 has, to our knowledge, never been investigated. L929 cells were treated with different concentrations of IL-1b (0-20 ng ml À1 ) in the absence or presence of 1000 U ml
À1
of IFNg. A 6-day exposure of L929 cells to IL-1b (up to 200 ng ml À1 ) or IFNg alone was not cytotoxic (Figure 1a and data not shown). However, combination of IL-1b plus IFNg killed half of the cells at a concentration of IL-1b as low as 40 pg ml
. As L929 cells are known to be very sensitive to TNF cytotoxicity and because IL1b has previously been shown to induce the production of TNF in dendritic cells (Kobayashi et al., 2004) , we first examined whether there could be a role for endogenous TNF in the cytotoxic effect of IL-1b. However, we were unable to detect any TNF in the culture medium of IL-1/IFNg-treated L929 cells as measured in a sensitive TNF bioassay with a detection limit of 1 pg ml À1 TNF (data not shown). To fully exclude a potential contribution of TNF, we also examined the effect of IL-1b/IFN-g on the TNFresistant L929r1 cells. These cells were found to be as sensitive to IL-1b/IFNg-induced cell death as the TNFsensitive L929 cells (Figure 1b ), further excluding a role for TNF in the cytotoxic effect of IL-1b.
IL-1b/IFNg induces caspase-independent L929 cell necrosis While performing the cell viability experiments, clear morphological differences were observed for L929 cells treated with IL-1b in combination with IFNg as compared to untreated cells or cells treated with IL-1b or IFNg alone. Control cells grew as a flat monolayer of cells with distinct cell borders, which was similar for IL-1b-or IFNg-treated cells (Figure 2a ). Treatment with IL-1b plus IFNg however resulted in morphological changes that included cell swelling and the appearance of cytoplasmic vacuoles, changes that are consistent with a necrotic form of cell death (Festjens et al., 2006) . In contrast to the essential role of caspases in apoptosis, necrosis is known to proceed independently from caspases (Festjens et al., 2006) . We therefore also studied the requirement for caspases in IL-1b/IFNginduced cell death by analysing the effect of different irreversible caspase inhibitors, namely z-YVAD-cmk, z-DEVD-cmk and z-VAD-fmk. z-YVAD-cmk predominantly inhibits caspase-1, z-DEVD-cmk predominantly inhibits caspase-3, -6 and -7, while z-VAD-fmk is a broad-spectrum caspase inhibitor (Earnshaw et al., 1999) . None of these caspase inhibitors had any effect on IL-1b/IFNg-induced L929 cell death ( Figure 2b ). In contrast, z-VAD-fmk sensitized L929 cells to TNFinduced necrosis (data not shown), which is in agreement with previous observations (Vercammen et al., 1998) . In addition, we investigated IL-1b/IFNginduced cell death of L929CrmA cells that stably express the cowpox virus protein CrmA, which is a specific inhibitor of caspase-1 and caspase-8 (Garcia-Calvo et al., 1998). Yet, this cell line was equally sensitive to IL-1b/IFNg-induced cell death as the control L929 cells (Figure 2c ). Finally, we also examined the potential activation of caspases in response to IL-1b/IFNg by measuring caspase-3 activity in L929 cell extracts on the fluorescent substrate Ac-DEVD-AFC. Since caspase-3 is an executioner caspase that is a downstream target of caspases involved in both the intrinsic and extrinsic pathways of apoptosis, activation of any caspase can be expected to result in the cleavage of Ac-DEVD-AFC. However, we observed no substantial caspase activity in L929 cells treated with IL-1b, IFNg or their combination (data not shown). Altogether, these findings demonstrate that L929 cell death in response to IL-1b/ IFNg treatment does not require the activation of caspases. À1 IL-1b in the absence or presence of 1000 U ml À1 IFNg as indicated. Cellular morphology was analysed by phase-contrast microscopy. (b) Effect of different caspase inhibitors on IL-1b/IFNg-induced cell death. L929 cells were treated for 6 days with different doses of IL-1b in the presence of 1000 U ml À1 IFNg. One hour before the start of treatment the cells also received z-VAD-fmk (25 mM), z-YVAD-cmk (50 mM) or z-DEVD-cmk (50 mM) as indicated. Cell survival was quantified in an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Treatment with IL-1b, IFNg or caspase inhibitors alone had no effect on cell survival. Results are representative of three independent experiments. (c) Effect of CrmA expression on IL-1b/IFNg-induced cell death. L929 and L929CrmA cells were treated for 6 days with different doses of IL-1b in the presence of 1000 U ml À1 IFNg. Cell survival was quantified in an MTT assay. Treatment with IL-1b or IFNg alone had no effect on cell survival. Results are representative of three independent experiments. NO mediates IL-1b/IFNg-induced L929 cell death IL-1b is known to induce the production of NO in islet b-cells. In addition, IL-1b-induced b-cell death has been shown to be NO-dependent, although this is still debated (Liu et al., 2000; Eizirik and Mandrup-Poulsen, 2001 ). To investigate the mechanism of IL-1b/IFNginduced L929 cell death, we initially examined whether IL-1b affected the production of NO in these cells. Treatment with IL-1b or IFNg for up to 4 days did not result in any detectable production of nitrite, an oxidative metabolite of NO (Figure 3a) . However, correlating with their potential to induce L929 cell death, combined treatment with IL-1b and IFN-g resulted in significant NO production after 1 day, which further increased with time. Since NO induction by proinflammatory cytokines is thought to result from de novo expression of iNOS (Kleinert et al., 2003) , we investigated whether increased NO production in L929 cells was associated with increased iNOS expression. Indeed, immunoblotting of L929 cell lysates with iNOSspecific antibodies revealed a strong upregulation of iNOS in response to combined treatment with IL-1b and IFNg (Figure 3b ), whereas treatment with IL-1b or IFNg as such had no effect (data not shown). These results correlate with the specific production of NO in response to IL-1b plus IFNg.
To analyse whether increased NO production is involved in the cytotoxic effect of IL-1b/IFNg, we investigated whether the NOS inhibitor L-NAME could inhibit cell death. Treatment of L929 cells with increasing doses of L-NAME attenuated IL-1b/IFNg-induced cell death in a dose-dependent manner (Figure 3c ). These findings indicate that IL-1b-induced necrosis of L929 cells is dependent on the upregulation of iNOS and the associated production of toxic NO levels. Moreover, treatment of L929 cells for 5 days with 1 mM of the NO donor S-nitroso-N-acetyl-D,L-penicillamine also resulted in 60% cell death (data not shown), suggesting that increased NO production in response to IL-1b/IFNg treatment might be sufficient to induce cell death.
IL-1b/IFNg-induced iNOS and NO production in L929 cells is dependent on p38MAPK and IKKb IL-1b is a potent activator of p38MAPK and IKKb (Dunne and O'Neill, 2003) , which are known to be involved in the activation of NF-kB-dependent gene expression in response to IL-1b and other proinflammatory cytokines (Beyaert et al., 1996; Madrid et al., 2001) . Also in the L929 cells used in the present study, we could show a clear activation of p38MAPK and IKKb in response to IL-1b (data not shown). The pathways regulating iNOS expression seem to vary in different cells or different species. In most cells, activation of NFkB and signal transducer and activator of transcription (STAT)-1a and thereby activation of the iNOS promoter seems to be an essential step in the regulation of iNOS expression (reviewed by Kleinert et al., 2004) . Also p38MAPK activation has been implicated in IL1b-induced iNOS expression in insulin-producing cells and some other cell types (Larsen et al., 1998; Saldeen and Welsh, 2004; Kim et al., 2006b) . To investigate whether IL-1b/IFNg-induced production of iNOS and NO in L929 cells is dependent on p38MAPK and IKKb, we analysed IL-1b/IFNg-induced production of iNOS and NO by L929 cells in the presence of the p38MAPK inhibitor SB203580 (Cuenda et al., 1995) or the IKKb inhibitor sc-514 (Kishore et al., 2003) . Analysis of the effect of SB203580 or sc-514 on IL-1b/IFNg-induced MAPKAPK-2 phosphorylation and IkBa degradation, respectively, confirmed that these inhibitors inhibit IL-1b/IFNg-induced p38MAPK and IKKb activation in L929 cells (Supplementary Figure 1) . As shown Figure 3 Interleukin-1b (IL-1b)/interferon-g (IFNg)-induced necrosis of L929 cells is dependent on the induction of nitric oxide synthase (iNOS) and NO. (a, b) Cells were stimulated with 10 ng ml À1 IL-1b and 1000 U ml À1 IFNg for 0-4 days as indicated. In (a), culture supernatants were isolated and analysed for nitrite production using the Griess assay. In (b), the corresponding cell lysates were analysed for iNOS expression by western blotting. b-Actin expression was analysed as a control for equal loading of samples (lower panel). Treatment with IL-1b or IFNg alone had no effect on NO or iNOS production. (c) Cells were treated for 6 days with different doses of IL-1b in the presence of 1000 U ml À1 IFNg. One hour before the start of treatment the cells also received L-NAME at the concentrations indicated. Cell survival was quantified using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay. Treatment with IL-1b, IFNg or L-NAME alone had no effect on cell survival. Results are representative of three independent experiments. IL-1b induces NF-jB-dependent necrosis E Vercammen et al before, IL-1b/IFNg strongly induced iNOS protein expression as early as 1 day after treatment. However, iNOS expression was almost completely inhibited when cells were stimulated in the presence of the p38MAPK inhibitor SB203580 (Figure 4a ). Also treatment with the IKKb inhibitor sc-514 significantly reduced the induction of iNOS, although the inhibitory effect of sc-514 was less pronounced compared to the effect of SB203580. Similarly, we also tested the effect of the p38MAPK and IKKb inhibitors on IL-1b/IFNg-induced NO production. In line with their effect on iNOS expression, both inhibitors significantly attenuated IL-1b/IFNginduced NO production in L929 cells, with the effect of SB203580 being more pronounced than the effect of sc-514 (Figure 4b ). Altogether these observations indicate that the IL-1b-induced activation of p38MAPK and IKKb contributes to the inducible expression of iNOS and the production of NO in L929 cells.
IL-1b/IFNg-induced necrosis of L929 cells is p38MAPK and NF-kB dependent
The p38MAPK-and IKKb-dependent production of iNOS and NO in response to IL-1b/IFNg treatment of L929 cells suggests an essential role for these kinases in IL-1b/IFNg-induced necrosis of these cells. To test this further, we determined the survival rate of L929 cells that were treated with IL-1b and IFNg in the presence of different concentrations of the p38MAPK inhibitor SB203580 or the IKKb inhibitor sc-514. Both inhibitors significantly attenuated IL-1b/IFNg-induced cell death, especially at lower concentrations of IL-1b (Figures 5a and b) . The cell-death protective effect of the p38MAPK inhibitor SB203580 was a little bit more pronounced than the effect of the IKKb inhibitor, which correlates with their relative potential to inhibit iNOS and NO production (Figure 4) . The structurally related and selective p38MAPK inhibitor SB202190, which has been reported to be slightly more potent than SB203580 (Davies et al., 2000) , also protected L929 cells from IL-1b/IFNg-induced cell death more efficiently than SB203580 (Supplementary Figure 2) . Altogether these findings demonstrate the crucial role of p38MAPK and NF-kB in IL-1b/IFNg-induced necrosis of L929 cells.
Discussion
In this study we have described the ability of IL-1b to induce necrosis of L929 fibrosarcoma cells. Moreover, we revealed an essential role for the p38MAPK-and NF-kB-dependent production of NO in this process. IL-1b cytotoxicity required the presence of IFNg and an incubation time of several days. This resembles the well-described IFNg-induced sensitization Figure 4 Inhibitors of p38MAPK and IKKb attenuate interleukin-1b (IL-1b)/ interferon-g (IFNg)-induced production of nitric oxide synthase (iNOS) and NO. L929 cells were stimulated with 10 ng ml À1 IL-1b and 1000 U ml À1 IFNg for 0-4 days as indicated. One hour before the start of treatment the cells also received SB203580 or sc-514 at the concentrations indicated. In (a), cell lysates were analysed for iNOS expression by western blotting. b-Actin expression was analysed as a control for equal loading of samples (lower panel). In (b), the corresponding culture supernatants were isolated and analysed for nitrite production using the Griess assay. Treatment with IL-1b, IFNg or the inhibitors alone had no effect on NO or iNOS production. Results are representative of three independent experiments. IL-1b induces NF-jB-dependent necrosis E Vercammen et al of tumor cells to TNF (Fransen et al., 1986) . It has previously been shown that IL-1b plus IFNg is able to induce TNF expression in some cell types and a role for endogenous TNF production has been proposed in IL-1b/IFNg-induced apoptosis of islet b-cells (Yamada et al., 1993) . However, we could not detect any TNF or other cytotoxic activity in the culture supernatant of L929 cells that were incubated for several days with IL-1b and IFNg. Moreover, similar cytotoxic effects of IL-1b/IFNg were observed in the TNF-resistant L929 subclone. A role for TNF or another endogenously produced and secreted factor in IL-1b/IFNg cytotoxicity is therefore rather unlikely. Historically, apoptosis, necrosis and autophagy have been described by several morphological and biochemical criteria as three types of mammalian cell death (Golstein and Kroemer, 2007) . Morphological analysis of IL-1b/ IFNg-treated L929 cells revealed cell death by necrosis. This is further illustrated by our observation that caspase inhibitors are not able to prevent IL-1b plus IFNginduced L929 cell death, which is in agreement with a caspase-independent mechanism of necrosis (Festjens et al., 2006) . To our knowledge, IL-1b-induced necrosis of tumor cells and its underlying mechanisms have not been described before. We could show that the IFNginduced sensitization of L929 cells to IL-1b cytotoxicity is at least partially mediated by the synergistic effect of IFNg and IL-1b on iNOS expression and the corresponding production of toxic NO levels. These findings are similar to the proposed role of iNOS and NO in IL1b/IFNg-induced islet b-cell death (Cnop et al., 2005) . Previous studies have shown a complex regulation of iNOS transcription by several transcription factors including NF-kB and STAT1, which are activated by IL-1b and IFNg, respectively (Kleinert et al., 2004) . IL1b strongly activates NF-kB in L929 cells (data not shown) and the inhibitory effect of the IKKb inhibitor sc-514 on IL-1b/IFNg-induced iNOS expression confirms the essential role for NF-kB in IL-1b-induced iNOS expression in L929 cells. It is remarkable that treatment with either IL-1b or IFNg alone did not induce iNOS expression, indicating a cooperative effect between IL-1b-and IFNg-induced signaling pathways. The molecular mechanism of this cooperative effect is still unclear, but might involve amongst others a role for p38MAPK. Indeed, treatment of L929 cells with a p38MAPK inhibitor almost completely prevented IL-1b/IFNg-induced iNOS expression. p38MAPK is strongly activated by IL-1b and has already been shown to mediate the synergistic induction of iNOS by LPS and IFNg through STAT1-Ser727 phosphorylation in murine aortic endothelial cells (Huang et al., 2004) . On the other hand, the decrease in IL-1b/IFNg-induced iNOS expression in the presence of a p38MAPK inhibitor might also reflect a more direct role of p38MAPK in NF-kB transactivation (Beyaert et al., 1996) or in iNOS mRNA stabilization (Kleinert et al., 2004) .
Besides its well known role in the regulation of proinflammatory gene expression, NF-kB also plays a critical role in cell survival by regulating the expression of anti-apoptotic proteins (Kim et al., 2006a) .
In contrast, our findings demonstrate a cell death promoting function for NF-kB in tumor cells treated with IL-1b/IFNg. Although rare, there are other systems in which NF-kB promotes apoptosis (Perkins and Gilmore, 2006) , but a necrosis promoting effect as reported here has not yet been described. The seemingly paradoxical effects of NF-kB on apoptosis may result from the different expression of proteins that promote (for example, Fas, p53) or inhibit (XIAP, cFLIP and Bcl-X L ) apoptosis. Similarly, we suggest that the NFkB-dependent expression of iNOS and the subsequent production of NO signals necrosis in response to IL-1b/ IFNg. Numerous reports document the ability of NO to initiate apoptosis in b-cells, chondrocytes, neurons, smooth muscle cells and various tumor cells (Brune et al., 1998) . However, a pronecrotic effect of NO as reported in the present study is rare. Necrosis is usually considered to be uncontrolled, but recent research suggests that its occurrence and course might be tightly regulated (Golstein and Kroemer, 2007) . In fact, one of the best studied models of receptor-induced necrosis is the L929 fibrosarcoma cell line treated with TNF (Festjens et al., 2006) . In this model, TNF initiates a complex multi-step signal transduction pathway in which the signaling proteins FADD and RIP1 play an essential role. How activation of RIP1 eventually activates necrosis is still unclear. Previously it was shown that mitochondria-produced ROS are important players in the execution of necrotic cell death (SchulzeOsthoff et al., 1993) . Therefore, it is conceivable that RIP1 directly or indirectly targets mitochondria. More recently, RIP1 was shown to activate the ROS-generating Nox1 NADPH oxidase complex, arguing for a nonmitochondrial source of ROS (Kim et al., 2007) . However, FADD and RIP1 are not believed to be part of the IL-1 signaling pathway, making a role of these proteins in IL-1b-induced necrosis rather unlikely. Moreover, treatment of L929 cells with the antioxidant butylated hydroxyanisole (BHA; Supplementary Figure  3) or stable overexpression of Bcl-2 (data not shown) did not protect against IL-1b/IFNg-induced cell death, although both were protective against TNF-induced necrosis. ROS have also been suggested to contribute to sustained Jun N-terminal kinase (JNK) activation and consecutive necrotic cell death (Sakon et al., 2003; Kim et al., 2007) . However, also the treatment of L929 cells with the JNK inhibitor SP600125 was not protective against IL-1b/IFNg-induced cell death (data not shown), further excluding a role for ROS and JNK in this process. Necrotic insults have also been shown to lead to calpain-mediated lysosomal disruption with consecutive release of cathepsins (Golstein and Kroemer, 2007) . However, a role for lysosomal release of cathepsins in IL-1b/IFNg-induced necrosis is unlikely since we could not observe any protective effect of the lysosomotrophic agent chloroquine or the broad-spectrum cysteine protease inhibitor E64 (data not shown). We also tested the effect of necrostatin-1, which has recently been found in a screening for compounds that are able to inhibit TNF-induced necrosis (Degterev et al., 2005) . Whereas necrostatin-1 strongly protected against TNF-induced necrosis of L929 cells, this compound was not protective against IL-1b/IFNginduced cell death (Supplementary Figure 3) . Finally, in contrast to the essential function of p38MAPK, NF-kB and NO in IL-1b-induced necrosis as reported in the present study, TNF-induced necrosis of L929 cells proceeds independently from these signaling molecules ( (Beyaert et al., 1996; Festjens et al., 2006) ; Supplementary Figure 2 and data not shown). Altogether, these data indicate that TNF and IL-1b induce necrosis by largely different mechanisms, the details of which remain to be revealed in the future.
Combined treatment with TNF and IFNg is successfully used for the treatment of cancer under specific conditions such as isolated limb perfusion . Clinical trials of cancer patients with IL-1 have been performed before, but only resulted in an antitumor response of o5% to daily bolus IL-1 therapy, mainly due to tachyphylaxis (Smith et al., 1992; Janik et al., 1996) . Our observations suggest that combined treatment of IL-1b and IFNg might be more efficient. However, one should take into consideration that tumor cell necrosis in response to IL-1b/IFNg will also initiate massive inflammation, which is known to enhance tumor progression (Yoshimura, 2006) . On the other hand, stimulation of necrotic cell death may contribute to eradication of tumor cells that evade apoptosis as a result of increased expression of anti-apoptotic proteins or mutations in crucial pro-apoptotic proteins. Further studies will be needed to determine whether IL-1b/IFNg treatment has any potential for the treatment of cancer.
Materials and methods
Cell culture and reagents L929sA (referred as L929 in the main text) and L929r1 are two cell clones derived from the murine fibrosarcome cell line L929 that were selected for high TNF sensitivity and TNF resistance, respectively (Vanhaesebroeck et al., 1991 (Vanhaesebroeck et al., , 1992 . L929CrmA cells are stably expressing the cowpox serpin crmA (Vercammen et al., 1998) . All L929 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 0.4 mM sodium pyruvate and antibiotics. Cells were seeded in 96-well plates (3 Â 10 3 cells per well) in case of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT)-assays and in six-well plates (1-4 Â 10 4 cells per well) in all other cases. Recombinant murine IL-1b, TNF and IFNg were expressed in Escherichia coli and purified in our laboratory. TNF and IL-1b had a specific biological activity of 1.4 Â 10 8 and 3.65 Â 10 8 IU mg À1 purified protein, respectively, as determined with the international standard (code 88/532 and 93/ 668, respectively; National Institute for Biological Standards and Control, Potters Bar, UK). z-VAD-fmk (Bachem GmbH, Weil Am Rhein, Germany), z-YVAD-cmk (Bachem) or z-DEVD-cmk (Bachem) were dissolved at 100mM in dimethyl sulfoxide. NG-nitro-L-arginine methyl ester (L-NAME) and BHA were purchased from Sigma-Aldrich, St Louis, MO, USA. SB203580, SB202190, necrostatin-1 and sc-514 were from Calbiochem-Merck, Nottingham, UK.
Western blotting
Cells grown in six-well plates (1-4 Â 10 4 cells per well) were lysed at 4 1C for 15 min in 100-200 ml of phospho-p38MAPK lysis buffer (10 mM Tris-HCl pH 7.4, 100 mM NaCl, 1% Triton-X100, 1 mM EDTA, 1 mM EGTA, 20 mM Na 4 P 2 0 7 , 0.1% SDS and 10% glycerol) supplemented with the proteaseinhibitor cocktail Complete (Roche Diagnostics, Basel, Switzerland). Cell lysates were subsequently separated by SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose membranes under semidry transfer conditions. Immunodetection was with anti-iNOS antibodies (BD Transduction Laboratories, San Diego, CA, USA) and enhanced chemiluminescence according to the manufacturer's specifications (PerkinElmer Life and Analytical Sciences, Waltham, MA, USA). Monoclonal mouse anti-actin antibodies were from MP Biomedicals (Illkirch, France).
Cell death-assay Cells were seeded at 3000 cells per well in a 96-well plate and the next day treated with a serial dilution of IL-1 in the absence or presence of IFNg. Cell death was measured at different times after stimulation by the MTT assay (Mosmann, 1983) .
Nitrite determination
Nitrite production was determined by mixing 50 ml of cell culture medium with 50 ml of Griess reagent (Green et al., 1982) . The absorbance at 540 nm was measured, and nitrite concentrations were calculated from a sodium nitrite standard curve.
